With the FDA now rudderless following the revelation that commissioner Marty Makary, M.D., is stepping down, voices across biopharma have joined in support of the FDA’s former top drug regulator ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...
Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate ...
Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from ...
The framework would leverage existing safety data on approved drugs to provide new options to patients with unmet medical ...
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
As President Donald Trump lands in Beijing, one major industry is missing from his business delegation—pharma. | As President ...
Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is ...
Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results